Group 1: Company Performance - The company reported a total revenue of RMB 3.135 billion for the fiscal year ending December 31, 2025, representing a 17.0% decrease compared to the previous year [1][4] - The gross profit margin decreased to 72.3% from 75.0% in the previous year [1][4] - The annual profit increased by 13.1% to RMB 950 million, with earnings per share at RMB 1.26 [1][4] - The company declared an interim dividend of RMB 0.43 per share for 2026 [1][4] Group 2: Product and Market Developments - In 2025, the company successfully won bids for eight key products in the national Chinese medicine procurement alliance, covering treatment areas such as cardiovascular, respiratory, and digestive diseases [1][4] - The successful bids align with DRG/DIP payment requirements, enhancing the availability of quality medications at competitive prices for patients, which is expected to boost future market demand and sales [1][4] Group 3: Industry Trends - The traditional Chinese medicine granule industry has entered a period of deep adjustment, characterized by declining sales due to the implementation of national standards, normalization of provincial procurement, and ongoing healthcare cost control [2][5] - The company's sales revenue from traditional Chinese medicine granules decreased by 14.4% during the year [2][5] - The sales team is focused on expanding into target provinces, controlling costs, and enhancing regional and product competitiveness, with expectations of regaining growth as the industry stabilizes [2][5]
神威药业发布年度业绩 净利润9.5亿元同比上升13.1%